RxDoctor Payments Data

Gerald French, MD

Internal Medicine · Delaware, OHNPI 1710075510

Payments from drug & device makers

$1,582in general payments, 2019–2025

Across 163 payments — averaging $9.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$13
  • Sanofi-aventis U.S. LLC$12

What the payments were for

  • Food & beverage$1,55098%
  • Education$322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk161$1,557
AstraZeneca1$13
Sanofi-aventis U.S. LLC1$12

How this compares

$1,582 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$130,206
Medicare patients
642
Services billed
3,010

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide192$230,984
EliquisApixaban111$118,318
TrulicityDulaglutide76$118,196
JardianceEmpagliflozin78$64,414
MounjaroTirzepatide42$56,934
FarxigaDapagliflozin Propanediol43$48,043
JanuviaSitagliptin Phosphate46$38,757
XareltoRivaroxaban31$37,003
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$21,903
Tresiba Flextouch U-100Insulin Degludec17$21,202
Spiriva RespimatTiotropium Bromide14$14,298
SymbicortBudesonide/Formoterol Fumarate33$12,566
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$12,287
Lantus SolostarInsulin Glargine,hum.Rec.Anlog86$10,710
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate30$6,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,557$230,984192 claims
AstraZenecaFarxiga, Symbicort$13$60,60976 claims
Sanofi-aventis U.S. LLCLantus$12$2,39118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Delaware

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →